SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

KYTX

Kyverna Therapeutics, Inc.
NASDAQHealth Care

Latest close: 5.67 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 24, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 11, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
  3. Aug 11, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record16410 flagged findings
Reported transactions (Form 4)75since Feb 12, 2024 · and 40 other holdings
Corporate events (8-K)16since Sep 16, 2024

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-12share offering or dilution eventrecentOpen filing ↗
    “…had net losses of $ 39.7 million and $ 44.6 million for the three months ended March 31, 2026 and 2025, respectively. The Company…”
    +1 more passage from the same document
    • “…and $ 44.6 million for the three months ended March 31, 2026 and 2025, respectively. The Company had cash used in operations of $…”
  • 2026-05-12listing compliance noticerecentOpen filing ↗
    “…stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore…”
    +1 more passage from the same document
    • “…our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to…”
  • 2026-05-12capital return (buybacks/dividends)recentOpen filing ↗
    “…of certain of our subsidiaries to, among other things: • Incur additional debt; • Make certain investments and acquisitions; •…”
  • 2026-05-12Department of Justice inquiryrecentOpen filing ↗
    “…to health applications and other similar technologies and expanded breach notification requirements, which may add additional…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 164)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 24, 268-K ↗Current report · Communication to the market
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Bain Capital Life Sciences Opportunities III, LP · 4.8% · event on Jun 30, 26 · amendment
  • Aug 11, 2610-Q ↗Quarterly report
  • Aug 11, 268-K ↗Current report · Results
  • Jul 29, 26SCHEDULE 13G ↗Passive stake · BlackRock, Inc. · 5.1% · event on Jun 30, 26
  • Jul 27, 268-K ↗Current report · Entered a material agreement
  • Jul 9, 268-K ↗Current report · Entered a material agreement
  • Jun 2, 268-K ↗Current report · Shareholder vote results
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • May 20, 26Form 3 ↗Insider transaction
  • May 20, 26Form 4 ↗Insider transaction
  • May 18, 268-K ↗Current report · A senior executive left or was appointed
  • May 12, 2610-Q ↗Quarterly report
  • May 12, 268-K ↗Current report · Results
  • May 6, 26Form 4 ↗Insider transaction
  • May 6, 26Form 3 ↗Insider transaction
  • May 4, 268-K ↗Current report · Other events
  • Apr 22, 268-K ↗Current report · Communication to the market
  • Apr 22, 268-K ↗Current report · Communication to the market
  • Apr 20, 268-K ↗Current report · Communication to the market
  • Apr 17, 26Form 144 ↗Notice of proposed sale

164 filings on record, the oldest from Nov 1, 23.

Listing the 25 most recent filings of the 164 on record.

8-Ks, explained

Structure6Governance10
  • Jul 27, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jul 9, 26StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Governance4 senior executive changes2026show all 4hide
    • May 18, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Feb 24, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Feb 3, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jan 12, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Dec 18, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Nov 3, 25StructureTook on a new financial obligation+3 more in the same filing8-K 2.03 ↗
  • Sep 25, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Jun 30, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Mar 27, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Governance4 senior executive changes2024show all 4hide
    • Nov 26, 24GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Nov 13, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Oct 21, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Sep 16, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Dr. Beth C. Seidenberg ("Seidenberg")7.8%Dec 31, 25SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • GordonMD Global Investments LP7.0%Nov 13, 25SCHEDULE 13G ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • Michael P. Rubin6.1%Dec 31, 25SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.5.1%Jun 30, 26SCHEDULE 13G ↗
  • Bain Capital Life Sciences Opportunities III, LP4.8%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Dec 18, 25Buy$1000KWestlake BioPartners Opportunity Fund I, L.P.↗
  • Dec 18, 25Buy$1000KBETH C SEIDENBERG↗
  • Dec 15, 25Sell$293KKaren Marie WalkerChief Technology Officer↗
  • Feb 12, 24Buy$9.9MNorthpond Ventures III GP, LLC↗
  • Feb 12, 24Buy$20.0MGILEAD SCIENCES, INC.↗
  • Feb 12, 24Buy$9.9MBain Capital Life Sciences Investors, LLC↗
  • Feb 12, 24Buy$5.6MVida Ventures, LLC↗
  • Feb 12, 24Buy$13KVida Ventures, LLC↗
Stock compensation, tax and giftsshow the 27 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • May 27, 26Compensationamount n/aBETH C SEIDENBERG↗
  • May 27, 26Tax$36KChristi ShawExecutive Chairperson↗
  • Mar 13, 26Compensationamount n/aWarner Weston BiddleChief Executive Officer↗
  • Mar 13, 26Compensationamount n/aMARC GRASSOChief Financial Officer↗
  • Mar 13, 26Compensationamount n/aNAJI GEHCHANSee Remarks↗
  • Feb 24, 26Compensationamount n/aSravan Kumar Emany↗
  • Feb 24, 26Compensationamount n/aAndrew Craig Miller↗
  • Jan 12, 26Compensationamount n/aChristi ShawExecutive Chairperson↗
  • Jan 12, 26Compensationamount n/aChristi ShawExecutive Chairperson↗
  • Dec 15, 25Compensation$116KKaren Marie WalkerChief Technology Officer↗
  • May 29, 25Compensationamount n/aBETH C SEIDENBERG↗
  • May 29, 25Compensationamount n/aDANIEL K SPIEGELMAN↗
  • May 29, 25Compensationamount n/aChristi Shaw↗
  • Apr 11, 25Compensationamount n/aKaren Marie WalkerChief Technology Officer↗
  • Apr 11, 25Compensationamount n/aRyan Alexander JonesChief Financial Officer↗
  • Jun 6, 24Compensation$43KKaren Marie WalkerChief Technology Officer↗
  • May 28, 24Compensation$8KRyan Alexander JonesChief Financial Officer↗
  • May 28, 24Compensation$5KRyan Alexander JonesChief Financial Officer↗
  • Feb 12, 24Otheramount n/aNorthpond Ventures III GP, LLC↗
  • Feb 12, 24Otheramount n/aGILEAD SCIENCES, INC.↗
  • Feb 12, 24Otheramount n/aBain Capital Life Sciences Investors, LLC↗
  • Feb 12, 24Otheramount n/aBETH C SEIDENBERG↗
  • Feb 12, 24Otheramount n/aBETH C SEIDENBERG↗
  • Feb 12, 24Otheramount n/aFred E Cohen↗
  • Feb 12, 24Otheramount n/aVida Ventures, LLC↗
  • Feb 12, 24Otheramount n/aWestlake BioPartners Fund I, L.P.↗
  • Feb 12, 24Otheramount n/aWestlake BioPartners Fund I, L.P.↗

The full record holds 35 transactions and goes back to Feb 7, 24.

Its sector and its market

Kyverna Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Kyverna Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Kyverna Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
164 documents on file, from Nov 1, 2023 to Sep 24, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.